Focus: Rain Oncology is a public-stage oncology-focused biotechnology company founded in 2022, specializing in small-molecule therapeutics with a pipeline spanning solid tumors, breast cancer, and lung cancer indications.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Growing — net +9 jobs in 30d
19 jobs added vs 10 removed. Steady team buildout.
Rain Oncology offers high-risk, high-reward early-stage biotech opportunity suitable for scientists and operators seeking equity upside and portfolio diversification, but unsuitable for stability-focused professionals without sufficient capital.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rain Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rain Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo